Prothena Corporation plc Logo

Email this page: News Release

First-In-Human Assessment of PRX002, Prothena's Anti-Alpha Synuclein Antibody for Parkinson's Disease, Published in Movement Disorders Journal

For security reasons, registration is required before you can use this feature.
* Indicates required field